Posted On: 08/21/2015 12:36:49 PM
Post# of 72443
Here's what a deal with big pharma can look like. This is for an MS drug. That is a big market, but not nearly as big as, say, oncology or infectious diseases.
Quote:
Novartis will pay $300 million up front for GSK's ofatumumab, an antibody designed to block the CD20 protein. The Swiss drugmaker will hand over another $200 million once the treatment enters its first Phase III MS trial and up to $534 million more tied to development milestones. GSK is also due as much as 12% of future ofatumumab sales in MS and any other autoimmune indication, Novartis said.
(0)
(0)Scroll down for more posts ▼
